Trulieve: Revenue Decline Outweighs The EPS Beat, Hold Until Growth Returns

Trulieve's stock popped 5% pre-market on Tuesday after the company reported an adjusted EPS of $0.11 against estimates of $0.08. The headline beat was enough for some to frame it as a positive quarter. Then the market opened, the full quarter came into focus, and the stock gave that gain back, closing down 4.5% to $8.60.

The initial headline — "shares advance on earnings beat" — gets the story backward. The stock did not advance. It reversed into a decline once investors digested the numbers behind the beat. That reversal tells me the market is correctly reading what the adjusted EPS number hides: revenue fell 10% year-over-year, adjusted EBITDA fell 11%, and management declined to offer quantitative guidance for the third quarter or full year.

I'm maintaining a Hold. The valuation has reset enough after a 27% year-to-date decline that the stock isn't an obvious trap. But the operating evidence doesn't support a Buy yet. The core medical business is shrinking, cost leverage is moving in the wrong direction, and there's no near-term proof point that growth has turned the corner.

What the quarter actually showed

Trulieve reported $271 million in revenue for the quarter ended June 30, missing analyst estimates of roughly $274 million. That is a small miss in dollar terms, but the trend is the larger story. Revenue is down 10% from $302 million a year ago and down 2% sequentially from Q1. Over the trailing twelve months, revenue growth has essentially flatlined at -1.4%.

The GAAP income statement is unusable as a forward signal. The company posted a net loss of $406 million, driven by a $407 million non-cash charge from the June 3 deconsolidation of its Harvest adult-use business. That transaction segregated Trulieve's medical-only operations from mixed-use Harvest so the company could list on the NYSE — the first U.S. cannabis operator to do so. Trulieve retains a 90% economic interest in Harvest going forward.

Stripping out that one-time charge, adjusted net income came to $20 million, or $0.11 per share — the beat that sparked the pre-market pop. Gross margin for the medical-only segment was 63%, and adjusted EBITDA was $98 million at a 36% margin. Those profitability numbers are solid. The problem is the denominator.

Adjusted EBITDA of $98 million is down 11% from $111 million a year ago. Revenue is down 10%. SG&A expenses held steady at $102 million despite the revenue decline, pushing SG&A as a percentage of revenue to 37.6% from 33.5% a year ago. Expense discipline hasn't kept pace with revenue erosion.

The cash flow story has legs

Here's where the story is less weak. Operating cash flow came in at $53 million and free cash flow at $32 million. Over the trailing twelve months, free cash flow has surged to $224 million, up 532% year-over-year. The company sits on $325 million in cash against roughly $289 million in debt. The balance sheet isn't stretched.

That cash generation is real, and it's one reason the stock isn't freefalling. Trulieve also announced a $50 million share repurchase authorization, which is a modest signal of management confidence at current levels. But the Q2 free cash flow number of $32 million is down roughly 54% from $70 million a year ago, and the annualized run rate from a single quarter is a small base to extrapolate from.

The valuation test

At $8.60, Trulieve has a market cap of $1.65 billion and an enterprise value of $1.41 billion. The stock trades at 1.4 times trailing sales, 4.4 times EV/EBITDA, and 1.4 times book value.

Those multiples are undeniably cheap for a company with its gross margin profile and cash generation. A 4.4x EV/EBITDA multiple is the kind of number that usually appears on distressed industrials or turnaround stories, not on a business with 60% gross margins and positive free cash flow. The 27% decline year-to-date has compressed the multiple significantly from where it stood.

But cheap has to buy enough time for the operating story to stabilize. The stock is cheap for a reason: revenue is declining, EBITDA is declining, and there's no quantitative guidance that tells investors when, or whether, the business reaccelerates. The management team said Q3 revenue should be "comparable" to Q2 medical-only revenue of $222 million, which would continue the decline trajectory.

The catalyst clock

Three potential catalysts matter for the next two quarters.

Federal policy. The reclassification of medical marijuana to Schedule III and the elimination of Section 280E tax penalties on state-licensed medical operations are real, material shifts. Trulieve filed DEA registration applications for its 206 retail locations. If 280E relief actually flows through to bottom-line cash in the second half, that's a direct boost to net income and free cash flow. The timing is uncertain but the direction is favorable.

Georgia. Patient enrollment has surpassed 45,000 and dispensary traffic reportedly tripled in early July following program expansions. Trulieve supplies nearly 20 independent pharmacies there. Georgia could become a meaningful revenue contributor in 2027, but the market currently has only seven dispensary licenses approved and Trulieve is waiting on an eighth.

Texas. Trulieve holds a conditional license for the Texas Compassionate Use Program and initial production construction is complete. Management sees the potential for 1.3 million patients in the state, currently sitting around 157,000. That's a large addressable market, but it remains conditional and distant.

What would change the rating

I'd upgrade to Buy if Trulieve delivers a quarter where revenue growth returns to positive territory, SG&A shows leverage as a percentage of sales, and management provides specific quantitative guidance. The current $0.11 adjusted EPS is a floor, not a ceiling. What I need to see is the growth engine restarting, not just the cost structure holding.

Conversely, the rating would flip negative if revenue declines persist into Q3 while management continues to withhold specific guidance. A stock at 4.4x EV/EBITDA can't fall forever, but a declining-revenue business with no catalyst timeline risks becoming a slow-motion value trap rather than a bargain.

The call

The competitor headline framing — "shares advance" — sold the pre-market reaction as the story. The real story is the full-day reversal and the declining operating metrics underneath a margin profile that isn't deteriorating fast enough to panic, but isn't improving enough to buy. The valuation is cheap. The balance sheet is stable. The regulatory environment is shifting in Trulieve's favor.

But the core medical business is still shrinking. Until revenue turns, guidance appears, and at least one of the federal or state catalysts converts into a revenue line item that's visible on the next income statement, this is a Hold.

Rating: Hold. Watch for Q3 revenue direction and any quantitative guidance in the next earnings call, approximately November 2026.